Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375841019> ?p ?o ?g. }
- W4375841019 abstract "Autoimmune bullous diseases (AIBDs) are a group of rare blistering dermatoses of the mucous membrane and/or skin. The efficacy, safety and treatment durability of intravenous immunoglobulin (IVIg) as an alternative treatment should be explored to systematically review the available literature regarding treatment outcomes with IVIg in AIBD patients. The predefined search strategy was incorporated into the following database, MEDLINE/PubMed, Embase, Scopus and Web of Science on 18 July 2022. Sixty studies were enrolled using Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The use of IVIg alone or combined with rituximab was reported in 500 patients with pemphigus, 82 patients with bullous pemphigoid, 146 patients with mucous membranes pemphigoid and 19 patients with epidermolysis bullosa acquisita. Disease remission with IVIg therapy and RTX + IVIg combination therapy were recorded as 82.8% and 86.7% in pemphigus, 88.0% and 100% in bullous pemphigoid and 91.3% and 75.0% in mucous membrane pemphigoid, respectively. In epidermolysis bullosa acquisita, treatment with IVIg led to 78.6% disease remission; no data were available regarding the treatment with RTX + IVIg in this group of patients. Among all the included patients, 37.5% experienced at least one IVIg-related side effect; the most common ones were headaches, fever/chills and nausea/vomiting. The use of IVIg with or without rituximab had a favourable clinical response in patients with AIBDs. IVIg has no major influence on the normal immune system, which makes its utilization for patients with AIBDs reasonable." @default.
- W4375841019 created "2023-05-10" @default.
- W4375841019 creator A5000495091 @default.
- W4375841019 creator A5014368565 @default.
- W4375841019 creator A5033408496 @default.
- W4375841019 creator A5046660410 @default.
- W4375841019 creator A5047550237 @default.
- W4375841019 date "2023-05-07" @default.
- W4375841019 modified "2023-09-24" @default.
- W4375841019 title "A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy" @default.
- W4375841019 cites W140438876 @default.
- W4375841019 cites W1887289690 @default.
- W4375841019 cites W188853335 @default.
- W4375841019 cites W1912711617 @default.
- W4375841019 cites W1963634637 @default.
- W4375841019 cites W1965699721 @default.
- W4375841019 cites W1968972064 @default.
- W4375841019 cites W1969087167 @default.
- W4375841019 cites W1981084641 @default.
- W4375841019 cites W1982430514 @default.
- W4375841019 cites W1988896965 @default.
- W4375841019 cites W1992158683 @default.
- W4375841019 cites W1993655313 @default.
- W4375841019 cites W2006779897 @default.
- W4375841019 cites W2010759771 @default.
- W4375841019 cites W2011191872 @default.
- W4375841019 cites W2025004995 @default.
- W4375841019 cites W2035326405 @default.
- W4375841019 cites W2040336606 @default.
- W4375841019 cites W2058681458 @default.
- W4375841019 cites W2060866289 @default.
- W4375841019 cites W206092631 @default.
- W4375841019 cites W2063033825 @default.
- W4375841019 cites W2069376212 @default.
- W4375841019 cites W2073248850 @default.
- W4375841019 cites W2079617476 @default.
- W4375841019 cites W2080572514 @default.
- W4375841019 cites W2090544680 @default.
- W4375841019 cites W2093957520 @default.
- W4375841019 cites W2108717668 @default.
- W4375841019 cites W2112167780 @default.
- W4375841019 cites W2125076165 @default.
- W4375841019 cites W2127411895 @default.
- W4375841019 cites W2130264575 @default.
- W4375841019 cites W2135749720 @default.
- W4375841019 cites W2152708305 @default.
- W4375841019 cites W2158319513 @default.
- W4375841019 cites W2158950814 @default.
- W4375841019 cites W2162787327 @default.
- W4375841019 cites W2169907270 @default.
- W4375841019 cites W2171359654 @default.
- W4375841019 cites W2179292527 @default.
- W4375841019 cites W2198382301 @default.
- W4375841019 cites W2259040952 @default.
- W4375841019 cites W2282097493 @default.
- W4375841019 cites W2317276018 @default.
- W4375841019 cites W2376674059 @default.
- W4375841019 cites W2521492798 @default.
- W4375841019 cites W2552494309 @default.
- W4375841019 cites W2583703195 @default.
- W4375841019 cites W2756129260 @default.
- W4375841019 cites W2781663420 @default.
- W4375841019 cites W2792259264 @default.
- W4375841019 cites W2793098491 @default.
- W4375841019 cites W2804781394 @default.
- W4375841019 cites W2808483624 @default.
- W4375841019 cites W2884627075 @default.
- W4375841019 cites W2889659185 @default.
- W4375841019 cites W2890880826 @default.
- W4375841019 cites W2891027494 @default.
- W4375841019 cites W2951855787 @default.
- W4375841019 cites W2953393878 @default.
- W4375841019 cites W2965781592 @default.
- W4375841019 cites W2966593624 @default.
- W4375841019 cites W2976364218 @default.
- W4375841019 cites W3011870969 @default.
- W4375841019 cites W3012132918 @default.
- W4375841019 cites W3015579738 @default.
- W4375841019 cites W3035222237 @default.
- W4375841019 cites W3044438836 @default.
- W4375841019 cites W3045834283 @default.
- W4375841019 cites W3081567385 @default.
- W4375841019 cites W3092613619 @default.
- W4375841019 cites W3111529194 @default.
- W4375841019 cites W3117652431 @default.
- W4375841019 cites W3118121151 @default.
- W4375841019 cites W3120633077 @default.
- W4375841019 cites W3155323546 @default.
- W4375841019 cites W3176954326 @default.
- W4375841019 cites W3178453884 @default.
- W4375841019 cites W3203789510 @default.
- W4375841019 cites W3211083144 @default.
- W4375841019 cites W4211003831 @default.
- W4375841019 cites W4221108339 @default.
- W4375841019 cites W4282565461 @default.
- W4375841019 cites W4283717174 @default.
- W4375841019 cites W4292574936 @default.
- W4375841019 cites W4300860941 @default.
- W4375841019 cites W4302303965 @default.
- W4375841019 cites W4362516565 @default.